Arthritis, Gouty
7 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) (NCT06846515) | Arthrosi Therapeutics | 2025-03-11 |
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) (NCT06439602) | Arthrosi Therapeutics | 2024-06-26 |
| The MAD Study of SSGJ-613 in Healthy Subjects (NCT05966701) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2023-08-10 |
| Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout (NCT05253833) | Arthrosi Therapeutics | 2022-08-12 |
| Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients (NCT05119686) | Arthrosi Therapeutics | 2021-11-16 |
| Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout (NCT00663169) | Novartis | 2008-04-01 |
| Celebrex In Acute Gouty Arthritis Study (NCT00549549) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2008-02-01 |
Track Arthritis, Gouty automatically
Every clearance here is in the API, with alerts when new ones post.